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Introduction
Parvoviruses are a family of small viruses comprising two subfamilies, the Parvovirinae that infect vertebrates, including man, and the Densovirinae that infect invertebrates such as insect and shrimp species. These viruses depend, due to their limited genome content, on enzymes and precursors present during the S-phase of the cell for their replicative functions and thus show a proclivity for actively dividing cells. Consequently, many parvoviruses, such as the porcine parvovirus (1) (PPV) 1 and the human B19 (2) parvovirus, are fetotropic, resulting in abortions, or have a predisposition to infect other mitosis-active tissues such as transformed cells ("oncolytic property") (3).
These nonenveloped, icosahedral viruses have a diameter of about 25 nm and contain a linear, single-stranded DNA genome of about 4-6 kb. The structure of several parvovirus capsids has been solved to near-atomic resolution, whereas the DNA is only partly ordered (4, 5) .
The capsid is composed of 60 structurally equivalent protein subunits, each containing a β-barrel jelly-roll in which some loops between the β-strands intertwine with loops from neighboring subunits and cover the viral surface for specific functions such as recognition of cellular receptors. About 10 out of the 60 capsid proteins have N-terminal extensions that are required for infectivity, in particular for cell entry and DNA delivery to the nucleus (6) (7) (8) . On the other hand, the C-terminal common structure (50-70 kDa), shared by all structural proteins of the virus, suffices to form capsids and to package DNA. The N-terminal extensions are not visualized in the X-ray structures, suggesting that they are disordered.
Recently, we have identified a phospholipase A 2 (PLA 2 ) motif in the N-terminal extension ("unique part") of the largest capsid protein, referred to as VP1, in about 30 different parvoviruses (8) . This domain, or its expressed form, has been coined as VP1up (8) . Its sequence similarity with sPLA 2 s is very weak and is mainly restricted to the catalytic site histidine and aspartate residues and the GXG calcium binding motif. The viral PLA 2 motifs lack cysteines, unlike all other previously characterized sPLA 2 s. In contrast, multiple disulfide bonds are a hallmark of all non-parvoviral sPLA 2 s and are used as the basis for their classification.
Moreover, viral PLA 2 s lack the long loop between the α-helices that contain the active site residues of classical sPLA 2 s.
Recombinant VP1up produced in E. coli was shown to display enzymatic activity toward phosphatidylcholine (8) . A number of point mutations in the E. coli expressed VP1up led to a significant decrease in PLA 2 enzymatic activity. These mutations were also introduced into the PPV genome in order to investigate the role of VP1 PLA 2 activity in the context of the viral cycle. Mutations that decrease enzymatic activity of VP1 (e.g.10 4 -fold) displayed a more than proportional decrease in infectivity. Confocal microscopy and in situ hybridization studies showed that PLA 2 -knockout mutants of the virus accumulated in the late endosome and lysosome and failed to deliver the viral DNA to the nucleus (8) . Moreover, complementation studies indicated that PLA 2 activity must be present in cis with the replication-competent DNA (e.g. in the same particle) for viral DNA to accumulate and replicate in the nucleus (8, 9) . Surprisingly, the PLA 2 enzymatic activity toward phosphatidylcholine-detergent mixed micelles measured using either expressed viral PLA 2 or virus particles varies up to 3 orders of magnitude among different parvoviruses (8) . It is not known whether this is due to intrinsic differences in the enzymatic efficiency of the VP1up domain or to other factors. To address this issue and to carry out a more detailed study of the interfacial kinetic and binding properties of parvoviral PLA 2 s, we cloned and expressed in E. coli the VP1up proteins from the parvoviruses B19, PPV, and AAV2, that each belong to a different genus of the Parvovirinae subfamily. We also studied PLA 2 enzymatic activity of a variant of the unique VP1up from PPV, lacking 58 amino acids from its C-terminus (denoted M33) (8) and the sensitivity of the VP1up proteins to compounds that are potent inhibitors of previously characterized sPLA 2 s. Finally, the ability of the VP1 proteins to liberate fatty acids from mammalian cells was investigated as well. This investigation could explain if the protein is able to hydrolyze the phospholipids membrane facilitating the penetration of the virus into the cells.
Materials and methods

Materials.
The plasmid pBAD/Thio-TOPO vector, which produces N-terminal thioredoxin fusion proteins with a carboxy-terminal His tag in E. coli, from Invitrogen was used. Nonradiolabeled and radiolabelled phospholipids were obtained from Avanti Polar Lipids Inc., and
Perkin-Elmer Life Sciences, respectively. Recombinant FABP, human group IIA sPLA 2 and human group X sPLA 2 were prepared as described (10) .
Cloning, expression, and purification of VP1up proteins. The pBAD2TEV expression vector was constructed by inserting 5'aga tcc gaa aac ctg tat ttt cag ggc aga tct gaa ttc gaa ctc gag ctc tct aga gaa aac ctg tat ttt cag ggc cct aga (bold: coding for ENLYFQG, the TEV protease site; italics: a polylinker (BglII, EcoRI, SfuI, XhoI, SstI, XbaI)) into the pBAD/Thio-TOPO vector using the TOPO (vaccinia virus topoisomerase-based) cloning technology (Invitrogen). The correct orientation of the insert was checked by sequencing. A protein expressed by this vector would contain thioredoxin-TEV-insert-TEV-His(6) from its N-to its C-terminal position. The VP1ups shown in Table I were amplified by PCR using the primers with the appropriate restriction sites listed in Table I . The amplicons were cloned into the pBAD2TEV expression vector using BamHI and XbaI sites for M33-VP1up, B19-VP1up and AAV2-VP1up and BamHI and XhoI sites for PPV-VP1up. Clones were analyzed to confirm their sequences, and correct clones were VP1up proteins eluted at ~35 min, and fractions with PLA 2 activity (determined using the spectrofluorimetric assay described below) were pooled and concentrated in a Centricon-10 (Millipore) to give a final protein concentration of 1.5-1.8 mg/ml. PPV-VP1up and M33-VP1up were judged to be ~90% pure by SDS-PAGE analysis. B19-VP1up was purified by gel filtration at 4°C on a Superdex 75 HR 10/30 column (Pharmacia) using 50 mM Tris-HCl, pH 8.0. Protein was loaded at 2 mg/ml with a flow rate 0.5 ml/min. B19-VP1up eluted at ~9 ml and was concentrated in a Centricon-10 to 1.5-1.8 mg/ml. To ensure complete removal of the His(6)-tagged TEV protease, the purified VP1up proteins were incubated with Ni-NTA resin (5 mg VP1up per ml of Ni-NTA resin) for 30 min at room temperature with gentle swirling. The mixture was centrifuged at 3,000 rpm, and the supernatant containing B19-VP1up was stored at -20°C after adding glycerol (see below Assay of VP1up PLA 2 activity. All of the VP1up proteins were assayed for PLA 2 activity using the spectrofluorimetric assay with PPyrPM (11). The specificity of the VP1up proteins for the sn-2 fatty acyl chain of phosphatidylcholine was determined using the dual-radiolabel approach with 1-stearoyl-2-[1-14 C]arachidonyl-phosphatidylcholine and 1-palmitoyl-2-[9,10-3 H]palmitoyl phosphatidylcholine as described (12) .
Immunogold detection of PLA2-containing domain of VP1up on PPV virions. PPV virus was
purified as descibed previously (1) . Both the sample submitted to a heatshock by one cycle of 4°C/65°C/4°C in a PCR thermocycler for 2 min at each step and the control sample were diluted with 10 mM Tris-HCl, pH 8.1 + 1 mM EDTA buffer to an optical density of 0.01 at 260 nm.
Virus in 100-µl samples was deposited onto nickel grids in a Beckman Airfuge ultracentrifuge at 20 psi for 5 min. After blotting with paper, the grids were deposited for 5 min on PBS and PBS/BSA(1%) drops, respectively and incubated for 2 hours with VP1up-specific polyclonal antibodies raised in a rabbit against E. coli-expressed M33 (antiserum diluted 1/100 in PBS). The Kinetic studies with phospholipid vesicles. Unilamellar vesicles (0.1 micron diameter of POPC, POPG, and POPS were prepared by extrusion in water as described (14) and stored for up to 2 days at 4°C (or frozen and re-extruded). Phospholipid concentrations in stock solutions were determined by phosphate analysis (standard ammonium molybdate method). Vesicle hydrolysis studies were carried with the indicated concentrations of vesicles (Table II) The calcium dependence of the hydrolysis of POPG vesicles by these viral VP1up proteins was studied by using the same assay as described above except that the Ca 2+ concentration was varied from 0 (buffer with 1 mM EGTA) to 2.5 mM. Phospholipid head group specificity studies. Studies to measure the preference of the VP1up proteins toward phospholipids with different polar headgroups were carried out using co-vesicles of POPA, POPC, POPE, POPG , POPI and POPS as described (15) .
Binding of
Release of arachidonic acid from CHO-K1 cells. CHO-K1 cells were cultured in Ham's F12
medium with 10% FCS, 2 mM glutamine, and the antibiotics penicillin and streptomycin. Cells were cultured in 24-well plates containing 1 ml medium per well. When cells reached ~80% confluence, 0.1 µCi of 3 H-arachidonic acid (~100 Ci/mmol, American Radiolabeled Chemicals, Inc.) was added per well. After 24 hr at 37°C (humidified atmosphere with 5% CO 2 ), cells were washed three times with complete medium, and 1 ml of complete medium was added. VP1up protein was then added in amounts as given in the legend to Figure 6 . The medium was removed after the indicated time period at 37°C (see legend to Figure 6 ) and centrifuged briefly to pellet any dislodged cells, then 0.5 ml of supernatant was submitted to scintillation counting. The cell layer remaining in the well was treated with trypsin/EDTA and the cell suspension submitted to scintillation counting. Arachidonic acid release is expressed as a percentage of cpm released to the culture medium divided by total cpm (released plus cell associated).
Results
Cloning, expression, and purification of parvovirus VP1up PLA 2 -like proteins. The regions of the viral DNAs coding for PLA 2 from 3 different parvoviruses proteins (PPV-VP1up, M33-VP1up, AAV2-VP1up, and B19-VP1up), were amplified by PCR and the products inserted into a bacterial expression vector. The N-terminal thioredoxin and the C-terminal His(6) affinity tag in these fusion proteins were released from the VP1up domain by cleavage with TEV protease.
Typically, 5-fold higher expression levels of fusion proteins were obtained using a host strain that contains extra copies of tRNA genes which recognize codons that are rare in E. coli (BL21-CodonPlus (DE3)-RIL) compared to expression in the standard strain BL21(DE3).
Chromatography of M33-VP1up on a Ni-NTA column followed by a Heparin-Sepharose column gave a protein that was >99% pure (Figure 1 ) whereas PPV-VP1up eluted as two bands, as
shown by SDS-PAGE (Figure 1 ), due to the incomplete cleavage of the fusion protein by TEV protease. The slower moving band could be removed by passing the TEV digestion mixture again through a Ni-NTA column (not shown). B19-VP1up and AAV2-VP1up were purified to near homogeneity ( Figure 1 ) by passage over an Ni-NTA column, followed by a gel filtration column, and finally a second Ni-NTA. Using this expression system, yields of 3-5 mg per liter of bacterial culture were obtained for each protein of the four viral PLA 2 s.
VP1up proteins are active PLA 2 s. Initially, the specific activity of the 4 expressed VP1up proteins were tested using the fluorimetric assay with vesicles of the anionic phospholipid PPyrPM (11) . Results (Table II) showed specific activities of 9.7 and 16 µmol/(min-mg),
respectively, for PPV-VP1up and M33-VP1up. On the other hand, B19-VP1up and AAV2-VP1up were about 2 orders of magnitude less active than PPV-VP1up and M33-VP1up on PPyrPM vesicles (Table II) . The kinetic data obtained with these recombinant VP1up proteins, produced in a heterologous host, established that these viral proteins are capable of functioning as PLA 2 s.
PPV externalizes its PLA 2 domain following heat treatment. Previously, we observed that the PLA 2 activity of PPV virus was greatly enhanced when the capsid was chemically disrupted, or when the virus was submitted to a thermal shock (8) , indicating that the PLA 2 -bearing domain of VP1 of PPV is buried within the native virus particle and needs to be externalized for PLA 2 activity of the virus on membranes. In order to examine whether heat treatment of PPV exposes the PLA 2 domain on intact viral particles, we used immunogold electron microscopy to visualize the VP1up domain of PPV using a polyclonal antiserum raised in rabbits againsts E. coli- Maximum activity is seen in the pH range 6-7 for the 4 viral PLA 2 s, and activity falls as the pH is lowered or raised from this range. Next, we determined the specific activities of the viral PLA 2 s on vesicles of phospholipid with different polar head groups. Table II gives the values for the hydrolysis of POPC, POPS, and POPG vesicles. The specific activities on these vesicles are a reflection both of the interfacial binding of these enzymes to the vesicle surface and the catalytic efficiency for the hydrolysis of different phospholipids used (15) . As for sPLA 2 s (15), POPG vesicles were the best substrate for the 4 different viral PLA 2 s (Table II) . PPV-VP1up and M33-VP1up PLA 2 s were highly active on POPC, POPS, and POPG vesicles. Thus, the 58 amino acids that are present on the C-terminus of PPV-VP1up but deleted in M33-VP1up are not required for the action on phospholipid vesicles. As with PPryPM, B19-VP1up and AAV2-VP1up were much less active than M33-VP1up and PPV-VP1up on POPC, POPS, and POPG vesicles (Table II) .
We also studied the substrate specificity of viral PLA 2 s on mixed vesicles of POPC, POPE, POPS, POPA, POPI and POPG and used combined HPLC-electrospray ionization mass spectrometry to quantify the amount of each lysophospholipid produced before 20% of the total phospholipid in the mixed substrate vesicles had been hydrolyzed (15) . In this experiment, the substrate specificity is not influenced by differential affinity of the PLA 2 to vesicles of different phospholipid composition and thus gives an indication of the intrinsic substrate specificity of the active site toward phospholipids with different polar headgroups. Results shown in Figure 4 indicate that all 4 VP1up proteins hydrolyze POPG, POPC, and POPA with high efficiency, POPE and POPS are slightly less preferred, and POPI is hydrolyzed only very poorly. Thus it appears that parvoviral PLA 2 s do not contain a well defined pocket for binding phospholipid polar head groups with high specificity. and PPV-VP1up indicated that the 58 amino acid C-terminal extension present in PPV-VP1up had no effect on affinity of the protein for calcium.
Calcium-dependence of phospholipid hydrolysis by viral
Interfacial binding of VP1up proteins to phospholipid vesicles. We measured the binding of
VP1up proteins to sucrose-loaded phospholipid vesicles, which can be pelleted by ultracentrifugation. Diether phospholipids (dioleyl) were used to avoid hydrolysis of vesicles by bound VP1up proteins as binding studies were carried out in the presence of sufficient Ca 2+ to saturate the enzyme based on the kinetic studies described above (2 mM). Values of the equilibrium constant for the dissociation of enzyme from vesicles, K d , were expressed in terms of millimolar phospholipid in the outler leaftlet of the vesicles (half of the total phospholipid in the binding reaction).
The data in Table III show that PPV-VP1up binds to dioleyl phosphatidylcholine vesicles containing 10% or 30% dioleyl phosphatidylserine with equal affinity. AAV2-VP1up binds 2-to 5-fold tighter to vesicles than does PPV-VP1up. Thus a poor interfacial binding cannot be the reason that AAV2-VP1up has low catalytic activity relative to PPV-VP1up.
Inhibition studies with VP1up PLA 2 s. Nine potent and active-site directed inhibitors of classical sPLA 2 s were studied as potential inhibitors of the VP1up PLA 2 s (inhibitors structures given in (15)). Enzyme assays were carried out with PPyrPM. Remarkably, all of these inhibitors displayed little or no potency on the VP1up PLA 2 s (Table IV) given the low specific activity of these PLA 2 s on phospholipid vesicles (Table II) .
Discussion
In this study, we have carried out a detailed analysis of the interfacial kinetic and binding properties of 4 parvoviral PLA 2 domains. The specific activity of M33-PLA 2 of 621 µmol/(minmg) on POPG vesicles exceeded that for human group IIA PLA 2 on these vesicles and is among the most active sPLA 2 s known (15) . Human group IIA PLA 2 displays very poor activity on POPC vesicles compared to POPG vesicles because this enzyme binds poorly to zwitterionic phosphatidylcholine vesicles (10) . In this case, the reaction progress curve exhibits an acceleration because enzyme binding to zwitterionic vesicles is enhanced by the build-up of anionic reaction products in these vesicles (10) . In contrast, human group X PLA 2 binds well to both zwitterionic and anionic POPG vesicles, displays comparable specificity activity on both, and hydrolyzes phosphatidylcholine vesicles without an acceleration phase (10). All 4 viral PLA 2 s behaved more like human group X PLA 2 on POPC vesicles in that no acceleration phase was observed, and that the specific activities on zwitterionic and anionic phospholipid vesicles were comparable (Table II) .
The VP1up proteins from AAV2 and B19 parvoviruses display specific activities toward a variety of phospholipid vesicles that are 2-to 3-orders of magnitude lower. It may be noted that mouse and human groups IID, IIE, and XIIA sPLA 2 s also display specific activities that are 100-to 1,000-fold lower than the most active sPLA 2 s toward phospholipid vesicles (15) . The reasons for the relatively low activity of a subset of these PLA 2 s is not obvious from a comparison of their amino acid sequences of these enzymes as well as the X-ray structures of a subset of them. It is possible that the physiological substrates for these low-activity enzymes have structures distinct from those of standard phospholipids.
The rise in activity of the viral PLA 2 s as the pH is raised from 5 up to 6 or 7 may be due to the deprotonation of the active site histidine that is predicted to be present in VP1up PLA 2 s based on amino acid sequence alignment (8) . Classical sPLA 2 s also contain an active site histidine and display a similar rise in enzymatic activity with increasing pH with an apparent pK a value of about 6-7 (16-18).
The dependence of the viral PLA2 enzymatic activity on the calcium concentration is typical of the behavior of classical sPLA 2 s (15). It should be noted that the , and active site phospholipid binding also requires that the enzyme be bound to the interface of phospholipid vesicles since long-chain phospholipids have virtually no solubility in the aqueous phase (19) .
It was previously found that human group X sPLA 2 binds to 10% dioleyl phosphatidylserine/dioleyl phosphatidylcholine vesicles with a K d of 0.13 mM (10). In marked contrast, human group IIA sPLA 2 shows a dramatic dependence on the presence of >10-20%
anionic phosphatidylserine for binding to vesicles (10, 20, 21) , which is consistent with its well established function as a Gram positive bactericidal agent (22-24). Gram positive membranes are highly rich in acidic phospholipids, especially phosphatidylglycerol, and the high density of basic residues (lysines and arginines) on the surface of the group IIA enzyme is important for allowing this enzyme to penetrate the highly anionic cell wall of Gram positive bacteria (25, 26) .
With respect to interfacial binding, the VP1up proteins behave more like the human group X enzyme. This is consistent with the data in Table II showing that the viral PLA 2 s display similar specific activities on POPS and POPC vesicles. This suggests that VP1up PLA 2 s act on host cell membranes which are typically not rich in acidic phospholipids. VP1up domain PLA 2 activity requires sub-millimolar to millimolar calcium concentrations which suggests that they act either in the extracellular fluid or inside an intracellular organelle whose aqueous lumen is derived from the extracellular fluid. On the other hand, VP1up proteins lack disulfide bonds in contrast to the classical sPLA 2 s which contain several disulfides and are not expected to survive the reducing environment of the cytosol of mammalian cells.
The ability of these viral PLA 2 s to liberate arachidonic acid from CHO-K1 cells is reminiscent of the results obtained with human group X PLA 2 (10) . Both the viral and mammalian PLA 2 s are able to readily hydrolyze phosphatidylcholine vesicles (Table II) , and thus it was expected that the viral PLA 2 s could act on the outer monolayer of mammalian cells, which is rich in zwitterionic phospholipids. In contrast, human group IIA sPLA 2 binds weakly to phosphatidylcholine-rich membranes and fails to release arachidonic acid when added exogenously to mammalian cells at concentrations up to 1 µg/ml (16) .
The intact PPV virus particle undergoes a structural transition after heat shock that greatly enhances the PLA 2 enzymatic activity and externalizes the VP1up PLA 2 domain ( Figure   2 ). It is tempting to suggest that the PPV viral capsid may be induced, at physiological temperature, to undergo a similar structural transition to expose its PLA 2 domain during virus entry into host cells due to specific enviroment (e.g. in endosome) or particular receptors at the time and location the enzyme activity is required. In contrast, VP1up of B19 virus has been reported to be always exposed (27) and its low PLA 2 activity may be required to avoid deleterious side effects of higher activities. It is also tempting to speculate that the lack of disulfides in the viral PLA 2 chains could contribute to the inability to visualize these domains in the parvovirus X-ray structures (as noted above). Parvoviruses containing point mutations in the PLA 2 catalytic residues of the VP1up proteins are no longer infectious (8, 9) . Thus, PLA 2 inhibitors are expected to display antiviral activity. Unfortunately, previously described potent inhibitors of classical sPLA2s display almost no activity on VP1up enzymes. In this context, it will be interesting to determine the high-resolution structure of VP1up proteins. This would also reveal the fold of these enzymes which is difficult to predict at present because of the limited amino acid sequence homology between VP1up proteins and classical sPLA 2 s. Given the distinct structural features of parvovirus VP1up proteins including the lack of disulfides, it is proposed that these enzymes be classified as group XIII PLA 2 s, to follow the recent identification of group XIIB sPLA 2 s (28). Restriction site BamH1
Restriction site XbaI AAV-VP1up
(1-148)*
5' GCGGATCCATGGCTGCCGATGGTTATC 3'
Restriction site BamH1
Restriction site XbaI *Amplified region of VP1up contained between the restriction sites of the primers in the amplicons. 
